In the early breast cancer patients’ group, of the 12 responders, the 8/12 weakly positive patients were receiving anthracycline-based chemotherapy, and the 4/12 strongly positive patients were receiving maintenance anti-HER2 therapy at the time of the BNT162b2 COVID-19 vaccine. This evidence concerns the gene ERBB2 and breast carcinoma.